Takaisin Tulosta

Lipidilääkitys ja alaraajaiskemia

Lisätietoa aiheesta
Daniel Gordin
18.2.2021

Kirjallisuutta

  1. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116:1509-26 «PMID: 25908725»PubMed
  2. Allison MA, Criqui MH, McClelland RL ym. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006;48:1190-7 «PMID: 16979004»PubMed
  3. Garg PK, Biggs ML, Carnethon M ym. Metabolic syndrome and risk of incident peripheral artery disease: the cardiovascular health study. Hypertension 2014;63:413-9 «PMID: 24191289»PubMed
  4. Mach F, Baigent C, Catapano AL ym. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-188 «PMID: 31504418»PubMed
  5. Dyslipidemiat. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Sisätautilääkärien Yhdistys ry:n asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 2017 (18.12.2017)
  6. Aung PP, Maxwell HG, Jepson RG ym. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007;:CD000123 «PMID: 17943736»PubMed
  7. Antoniou GA, Fisher RK, Georgiadis GS ym. Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. Vascul Pharmacol 2014;63:79-87 «PMID: 25446168»PubMed
  8. Heart Protection Study Collaborative Group.. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007;45:645-654; discussion 653-4 «PMID: 17398372»PubMed
  9. Kumbhani DJ, Steg PG, Cannon CP ym. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014;35:2864-72 «PMID: 24585266»PubMed
  10. Murphy SA, Cannon CP, Blazing MA ym. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol 2016;67:353-361 «PMID: 26821621»PubMed
  11. Meade T, Zuhrie R, Cook C ym. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325:1139 «PMID: 12433762»PubMed
  12. Sabatine MS, Giugliano RP, Keech AC ym. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713-1722 «PMID: 28304224»PubMed
  13. Bonaca MP, Nault P, Giugliano RP ym. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018;137:338-350 «PMID: 29133605»PubMed